The 32nd Annual
Cancer Progress Conference

May 4-6, 2021

❝ Inspiring Cancer Progress through engaged stakeholder dialogue ❞



It is time for everyone to save the date for Cancer Progress! With the success of our 1st virtual event, it is our pleasure to announce our 32nd Annual and 2nd virtual.

With the success of our first virtual conference, we are looking to expand to three days and are considering adding a partnering component.

We are incredibly grateful for the donations we received during Cancer Progress 2020. With your help we raised close to $20,000 and donated to:




We are pleased to announce our day one keynote speaker!

Engineering the Future: Next Gen Platforms in Oncology

Tuesday, May 4, 2021 | 9:15 – 10:00 am EDT

Daniel S. Chen, MD, PhD

Chief Medical Officer

Cancer Progress Conference Panels Include...

Climbing the Highest Peak: Targeting PD-1/L1 Failures in Solid Tumors

Multifunctional Soluble Biologics: Binders, Binders Everywhere

Tumor Agnostic Development

Accelerated Development Paths

Endogenous Reprogramming: Anything One Can Do Ex Vivo, Can One Do In Vivo (and Do Better)?

Cell Therapy in Solid Tumors: Freedom of the Open Road

Validating New Platforms: Clinical Pain, Commercial Gain

Allogeneic Cell Therapy: Stocking the Shelf

Retention of Native Cell Signaling: Less is More

Heme Malignancies Transformed: An Idiosyncratic Comparison of Multiple Myeloma and AML

Value Panel

Investing in the Emerald City of Oncology Innovation: Platforms & Modalities & Targets, Oh My!

Let’s Make a Deal in Oncology: What’s Behind the Doors & Who Has the Keys?

...More panels TBD

Cancer Progress 2020 Panel Summaries

As a preview of the good things to expect from Cancer Progress 2021, we’re excited to roll out summaries of select sessions from Cancer Progress 2020, starting with a summary of the panel “Paradigm Shifting Platforms II – Non-IO: Targeting Better, Targeting the Intractable” that highlights the key opportunities and challenges of non-IO targeted approaches and how even they cannot be thought of independently from IO.


Paradigm-shifting platforms I, IO: Taking IO to the next Level

Paradigm-shifting platforms II, Non-IO: Targeting Better, Targeting the Intractable

Oncology Modalities Facing Off: Room for Many or One to Rule them All


Good array of opinions and technologies. Well curated

Andrew Allen, MD, PhD, President & CEO

Gritstone Oncology

As I like to say, Cancer Progress is THE BEST non-academic cancer conference out there. Again proving your staggering insight!

Michael G. King, Jr., Entrepreneur in Residence

Fortress Biotech Inc.

When we hear all the negatives from the experts on cell therapies and COVID—let’s think of Richard Feynman: “Science is the belief in the ignorance of the experts

Mark Simon, Managing Director


“Thank you for the opportunity. I felt privileged to be part of a panel composed of stellar leaders within the Oncology space.”

Noemi Rosa


“I really enjoyed the meeting as usual – great topics and speakers. I look forward to next year’s meeting!”

Richard Brian Gaynor, Sr. Vice President Global Development / Medical Affairs, Oncology Business Unit

Eli Lilly and Company